Why a diagnosis-specific hospital estimate matters
For international self-pay patients, the useful financial starting point is a specialist-reviewed treatment plan rather than a generic cancer price. The estimate should reflect the planned diagnostics, treatment modality, expected hospital or day-clinic care and known high-cost medicines or procedures; the final invoice can still change if the actual treatment episode differs.
Acute leukemia is often a multi-phase treatment pathway
Induction, consolidation and later treatment phases can involve different admissions, medicines, laboratory monitoring and supportive care. Ask whether the estimate covers one admission, one phase or the full planned course.
Molecular and bone-marrow diagnostics can be substantial
Morphology, flow cytometry, cytogenetics, molecular testing and measurable residual disease assessment can all affect treatment decisions and may need to be repeated or reviewed before therapy.
- Bone-marrow diagnostics
- Flow cytometry
- Cytogenetic and molecular testing
- High-cost anti-leukemia medicines
- Blood-product support
- Infection prevention and treatment
- Repeated inpatient admissions
- Stem-cell transplantation when indicated
Urgent treatment should not be delayed to wait for an overseas price
Some acute leukemias require rapid treatment. If the local hematology team considers treatment urgent, the patient should not postpone necessary care while waiting for visas, travel or an international quotation.
Official sources
Last source-reviewed 2026-08-30. Cost procedures and published service fees can change, so confirm current terms directly with the provider before transferring money or booking travel.
- International patient process and cost estimate — University Medical Center Hamburg-Eppendorf (UKE) ↗
- Cost Plan — LMU Klinikum International Patient Office ↗
- Finance for international patients — Heidelberg University Hospital ↗
- Acute Leukemia (ALL/AML) – patient information — National Center for Tumor Diseases Heidelberg ↗